Highly electronegative LDL from patients with ST-elevation myocardial infarction triggers Platelet activation and aggregation

Blood

Volumn 122, Issue 22, 2013, Pages 3632-3641

  Chan, Hua Chen ^a,b,c   Ke, Liang Yin ^a,c,d   Chu, Chih Sheng ^a,d   Lee, An Sheng ^b,e   Shen, Ming Yi ^b   Cruz, Miguel A ^f   Hsu, Jing Fang ^b   Cheng, Kai Hung ^a,d   Chan, Hsiu Chuan Bonnie ^d   Lu, Jonathan ^c   Lai, Wen Ter ^d   Sawamura, Tatsuya ^g   Sheu, Sheng Hsiung ^d   Yen, Jeng Hsien ^a,d   Chen, Chu Huang ^b,c,d,f  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c TEXAS HEART INSTITUTE   (United States)

^d KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e MACKAY MEDICAL COLLEGE   (Taiwan)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

^g NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; APOLIPOPROTEIN; CYCLIC AMP; GLYCOPROTEIN IIB; GLYCOPROTEIN IIIA; HIGHLY ELECTRONEGATIVE LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PADGEM PROTEIN; PROTEIN KINASE B; PROTEIN KINASE C ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEEDING TIME; BLOOD CLOTTING; CELL ADHESION; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; LIPOPROTEIN BLOOD LEVEL; MALE; METABOLIC SYNDROME X; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE RICH PLASMA; THROMBOSIS;

EID: 84888238211     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-05-504639     Document Type: Article

References (46)

1. Parguiña AF, Grigorian-Shamagian L, Agra RM, et al. Variations in platelet proteins associated with ST-elevation myocardial infarction: novel clues on pathways underlying platelet activation in acute coronary syndromes. Arterioscler Thromb Vasc Biol. 2011;31(12):2957-2964.
2. Vorchheimer DA, Badimon JJ, Fuster V. Platelet glycoprotein IIb/IIIa receptor antagonists in cardiovascular disease. JAMA. 1999;281(15):1407-1414.
3. Frossard M, Fuchs I, Leitner JM, et al. Platelet function predicts myocardial damage in patients with acute myocardial infarction. Circulation. 2004;110(11):1392-1397.
4. Huczek Z, Filipiak KJ, Kochman J, et al. Baseline platelet reactivity in acute myocardial infarction treated with primary angioplasty-influence on myocardial reperfusion, left ventricular performance, and clinical events. Am Heart J. 2007;154(1):62-70.
5. Wu CC, Wu SY, Liao CY, Teng CM, Wu YC, Kuo SC. The roles and mechanisms of PAR4 and P2Y12/phosphatidylinositol 3-kinase pathway in maintaining thrombin-induced platelet aggregation. Br J Pharmacol. 2010;161(3):643-658.
6. Marwali MR, Hu CP, Mohandas B, et al. Modulation of ADP-induced platelet activation by aspirin and pravastatin: role of lectin-like oxidized low-density lipoprotein receptor-1, nitric oxide, oxidative stress, and inside-out integrin signaling. J Pharmacol Exp Ther. 2007;322(3):1324-1332.
7. Patrono C, Garćia Rodríguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005;353(22):2373-2383.
8. Yusuf S, Mehta SR, Zhao F, et al; Clopidogrel in Unstable angina to prevent Recurrent Events Trial Investigators. Early and late effects of clopidogrel in patients with acute coronary syndromes. Circulation. 2003;107(7):966-972.
9. Roffi M, Chew DP, Mukherjee D, et al. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation. 2001;104(23):2767-2771.
10. Chen CH, Jiang T, Yang JH, et al. Low-density lipoprotein in hypercholesterolemic human plasma induces vascular endothelial cell apoptosis by inhibiting fibroblast growth factor 2 transcription. Circulation. 2003;107(16):2102-2108.
11. Ke LY, Engler DA, Lu J, et al. Chemical composition-oriented receptor selectivity of L5, a naturally occurring atherogenic low-density lipoprotein. Pure Appl Chem. 2011;83(9):1731-1740.
12. Lu J, Yang JH, Burns AR, et al. Mediation of electronegative low-density lipoprotein signaling by LOX-1: a possible mechanism of endothelial apoptosis. Circ Res. 2009;104(5):619-627.
13. Sánchez-Quesada JL, Benítez S, Ordóñez-Llanos J. Electronegative low-density lipoprotein. Curr Opin Lipidol. 2004;15(3):329-335.
14. Yang CY, Raya JL, Chen HH, et al. Isolation, characterization, and functional assessment of oxidatively modified subfractions of circulating low-density lipoproteins. Arterioscler Thromb Vasc Biol. 2003;23(6):1083-1090.
15. Lu J, Jiang W, Yang JH, et al. Electronegative LDL impairs vascular endothelial cell integrity in diabetes by disrupting fibroblast growth factor 2 (FGF2) autoregulation. Diabetes. 2008;57(1):158-166.
16. Tang D, Lu J, Walterscheid JP, et al. Electronegative LDL circulating in smokers impairs endothelial progenitor cell differentiation by inhibiting Akt phosphorylation via LOX-1. J Lipid Res. 2008;49(1):33-47.
17. Chang PY, Chen YJ, Chang FH, et al. Aspirin protects human coronary artery endothelial cells against atherogenic electronegative LDL via an epigenetic mechanism: a novel cytoprotective role of aspirin in acute myocardial infarction. Cardiovasc Res. 2013;99(1):137-145.
18. Fei H, Berliner JA, Parhami F, Drake TA. Regulation of endothelial cell tissue factor expression by minimally oxidized LDL and lipopolysaccharide. Arterioscler Thromb. 1993;13(11):1711-1717.
19. Tedgui A, Mallat Z. Apoptosis, a major determinant of atherothrombosis. Arch Mal Coeur Vaiss. 2003;96(6):671-675.
20. Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest. 2005;115(12):3378-3384.
21. Aviram M. Plasma lipoprotein separation by discontinuous density gradient ultracentrifugation in hyperlipoproteinemic patients. Biochem Med. 1983;30(1):111-118.
22. Englyst NA, Taube JM, Aitman TJ, Baglin TP, Byrne CD. A novel role for CD36 in VLDL-enhanced platelet activation. Diabetes. 2003;52(5):1248-1255.
23. Cruz MA, Diacovo TG, Emsley J, Liddington R, Handin RI. Mapping the glycoprotein Ib-binding site in the von willebrand factor A1 domain. J Biol Chem. 2000;275(25):19098-19105.
24. Washington AV, Gibot S, Acevedo I, et al. TREM-like transcript-1 protects against inflammation-associated hemorrhage by facilitating platelet aggregation in mice and humans. J Clin Invest. 2009;119(6):1489-1501.
25. Yang CY, Chen HH, Huang MT, et al. Proapoptotic low-density lipoprotein subfractions in type II diabetes. Atherosclerosis. 2007;193(2):283-291.
26. Chen CY, Hsu HC, Lee AS, et al. The most negatively charged low-density lipoprotein L5 induces stress pathways in vascular endothelial cells. J Vasc Res. 2012;49(4):329-341.
27. Li D, D'Angelo L, Chavez M, Woulfe DS. Arrestin-2 differentially regulates PAR4 and ADP receptor signaling in platelets. J Biol Chem. 2011;286(5):3805-3814.
28. Loeffen R, Spronk HM, ten Cate H. The impact of blood coagulability on atherosclerosis and cardiovascular disease. J Thromb Haemost. 2012;10(7):1207-1216.
29. Dosquet C, Weill D, Wautier JL. Cytokines and thrombosis. J Cardiovasc Pharmacol. 1995;25(Suppl 2):S13-S19.
30. Lee AS, Wang GJ, Chan HC, et al. Electronegative low-density lipoprotein induces cardiomyocyte apoptosis indirectly through endothelial cell-released chemokines. Apoptosis. 2012;17(9):1009-1018.
31. Lasky LA. Selectins: interpreters of cell-specific carbohydrate information during inflammation. Science. 1992;258(5084):964-969.
32. Frenette PS, Denis CV, Weiss L, et al. P-Selectin glycoprotein ligand 1 (PSGL-1) is expressed on platelets and can mediate platelet-endothelial interactions in vivo. J Exp Med. 2000;191(8):1413-1422.
33. Theilmeier G, Michiels C, Spaepen E, et al. Endothelial von Willebrand factor recruits platelets to atherosclerosis-prone sites in response to hypercholesterolemia. Blood. 2002;99(12):4486-4493.
34. Dong ZM, Chapman SM, Brown AA, Frenette PS, Hynes RO, Wagner DD. The combined role of P- and E-selectins in atherosclerosis. J Clin Invest. 1998;102(1):145-152.
35. Frenette PS, Johnson RC, Hynes RO, Wagner DD. Platelets roll on stimulated endothelium in vivo: an interaction mediated by endothelial P-selectin. Proc Natl Acad Sci USA. 1995;92(16):7450-7454.
36. Romo GM, Dong JF, Schade AJ, et al. The glycoprotein Ib-IX-V complex is a platelet counterreceptor for P-selectin. J Exp Med. 1999;190(6):803-814.
37. Totani L, Evangelista V. Platelet-leukocyte interactions in cardiovascular disease and beyond. Arterioscler Thromb Vasc Biol. 2010;30(12):2357-2361.
38. Dunlop LC, Skinner MP, Bendall LJ, et al. Characterization of GMP-140 (P-selectin) as a circulating plasma protein. J Exp Med. 1992;175(4):1147-1150.
39. André P, Hartwell D, Hrachovinová I, Saffaripour S, Wagner DD. Pro-coagulant state resulting from high levels of soluble P-selectin in blood. Proc Natl Acad Sci USA. 2000;97(25):13835-13840.
40. Kulkarni S, Dopheide SM, Yap CL, et al. A revised model of platelet aggregation. J Clin Invest. 2000;105(6):783-791.
41. Gawaz M, Neumann FJ, Dickfeld T, et al. Vitronectin receptor (alpha (v) beta3) mediates platelet adhesion to the luminal aspect of endothelial cells: implications for reperfusion in acute myocardial infarction. Circulation. 1997;96(6):1809-1818.
42. Chen M, Kakutani M, Naruko T, et al. Activationdependent surface expression of LOX-1 in human platelets. Biochem Biophys Res Commun. 2001;282(1):153-158.
43. Offermanns S. Activation of platelet function through G protein-coupled receptors. Circ Res. 2006;99(12):1293-1304.
44. Hunter RW, Mackintosh C, Hers I. Protein kinase C-mediated phosphorylation and activation of PDE3A regulate cAMP levels in human platelets. J Biol Chem. 2009;284(18):12339-12348.
45. Popović M, Smiljanić K, Dobutović B, Syrovets T, Simmet T, Isenović ER. Thrombin and vascular inflammation. Mol Cell Biochem. 2012;359(1-2):301-313.
46. Angiolillo DJ, Capodanno D, Goto S. Platelet thrombin receptor antagonism and atherothrombosis. Eur Heart J. 2010;31(1):17-28.